Common Mental Disorders — MCQs
On this page
A 37-year-old man with moderate depression has been taking sertraline 150mg daily for 8 weeks with 40% symptom improvement but remains functionally impaired. His GP considers next management steps. He has no other medical conditions and has not previously tried other antidepressants. Which strategy has the strongest evidence base for improving outcomes at this stage?
A 33-year-old woman with panic disorder and agoraphobia has been receiving graded exposure therapy as part of CBT. After successfully managing short trips to local shops, she attempts a bus journey but experiences a severe panic attack and immediately returns home. She now refuses further exposure tasks. How should her therapist proceed?
A 53-year-old woman with depression started on citalopram 20mg daily 10 days ago presents with confusion, agitation, tremor, hyperreflexia, and sweating. Temperature is 38.2°C. She also takes tramadol 100mg QDS for chronic back pain and St John's Wort which she didn't mention previously. What is the most likely diagnosis?
A 49-year-old man with panic disorder has been taking sertraline 100mg daily for 4 months with good control of panic attacks. He now reports experiencing 4-5 panic attacks per week again, despite medication compliance. On further questioning, he reveals he has started drinking 6-8 units of alcohol daily over the past 6 weeks to 'calm his nerves'. What is the most likely explanation for his deteriorating symptoms?
A 41-year-old woman presents with a 2-month history of low mood, anhedonia, and significant psychomotor retardation. She has difficulty getting out of bed and has been off work for 3 weeks. PHQ-9 score is 23. She has no suicidal ideation. Her GP considers referral thresholds. Which action is most appropriate?
A 35-year-old teacher with generalised anxiety disorder has been receiving CBT for 10 weeks with some improvement but continues to have significant functional impairment. She is reluctant to take medication but agrees to consider pharmacotherapy. She has no other medical conditions. According to NICE guidelines, which medication should be offered first-line?
A 58-year-old woman with recurrent depressive disorder has been taking fluoxetine 40mg daily for 6 weeks with minimal improvement. She reports persistent low mood, poor sleep, and has lost 4kg in weight. She mentions that her mother responded well to a 'different type of antidepressant' years ago. Examination reveals a blood pressure of 168/95 mmHg. Which antidepressant change should be avoided?
A 27-year-old woman presents to the emergency department with her third panic attack this month. She describes sudden onset of chest pain, palpitations, sweating, and a feeling of impending doom lasting 15-20 minutes. ECG shows sinus tachycardia. Troponin is negative. She is otherwise healthy. What is the most appropriate immediate management?
A 44-year-old man with treatment-resistant depression has failed to respond to adequate trials of two different SSRIs and venlafaxine. His psychiatrist considers augmentation therapy. He has type 2 diabetes and stage 3 chronic kidney disease. Which augmentation strategy requires the most careful monitoring in this patient?
A 31-year-old woman with panic disorder describes feeling increasingly anxious about having panic attacks in public places. She has started avoiding supermarkets and public transport. What psychological mechanism best explains the development of her avoidance behaviour?
Common Mental Disorders UK Medical PG Practice Questions and MCQs
Question 141: A 37-year-old man with moderate depression has been taking sertraline 150mg daily for 8 weeks with 40% symptom improvement but remains functionally impaired. His GP considers next management steps. He has no other medical conditions and has not previously tried other antidepressants. Which strategy has the strongest evidence base for improving outcomes at this stage?
- A. Continue sertraline at current dose for a further 4-6 weeks (Correct Answer)
- B. Increase sertraline to 200mg daily
- C. Switch to venlafaxine 150mg daily
- D. Add mirtazapine 15mg at night to sertraline
- E. Switch to cognitive behavioural therapy alone, discontinuing sertraline
Explanation: ***Continue sertraline at current dose for a further 4-6 weeks*** - A full trial of an antidepressant typically requires **8-12 weeks** at a therapeutic dose; given the patient's **40% symptom improvement** at 8 weeks, continued treatment at the same dose is likely to yield further benefits. - Clinical guidelines support maintaining the current regimen when there's evidence of **partial response**, as many patients achieve **full remission** with more time on the same dose. *Increase sertraline to 200mg daily* - Increasing the dose is generally considered when there is **minimal or no response** after an adequate trial, not when a patient has already shown significant partial improvement. - Higher doses can lead to an increased incidence of **dose-dependent side effects** without necessarily providing additional benefit when the current dose is already partially effective. *Switch to venlafaxine 150mg daily* - Switching to a different antidepressant is typically reserved for cases where the initial drug has proven **ineffective** or is not tolerated after a full trial, which is not the situation here. - Prematurely switching risks losing the **established partial response** and introduces a new set of potential **adverse effects** and withdrawal symptoms from sertraline. *Add mirtazapine 15mg at night to sertraline* - This **augmentation strategy** is usually reserved for **treatment-resistant depression**, generally defined as inadequate response to two or more full trials of monotherapy. - Initiating augmentation at this stage is overly aggressive given the patient's partial response and could increase the risk of **serotonergic side effects** without established need. *Switch to cognitive behavioural therapy alone, discontinuing sertraline* - Discontinuing a medication that is providing a **partial therapeutic effect** is generally not recommended for moderate depression, as it risks relapse or worsening symptoms. - For moderate depression, **cognitive behavioural therapy (CBT)** is most effective when used as **adjunctive therapy** alongside antidepressants, rather than as a replacement for an effective medication.
Question 142: A 33-year-old woman with panic disorder and agoraphobia has been receiving graded exposure therapy as part of CBT. After successfully managing short trips to local shops, she attempts a bus journey but experiences a severe panic attack and immediately returns home. She now refuses further exposure tasks. How should her therapist proceed?
- A. Increase the hierarchy gradient by adding intermediate steps before attempting bus travel (Correct Answer)
- B. Prescribe benzodiazepines to use before exposure tasks
- C. Switch to medication-based treatment as psychological therapy has failed
- D. Encourage immediate re-attempt of the bus journey to prevent avoidance consolidation
- E. Discontinue exposure therapy and focus on cognitive restructuring techniques only
Explanation: ***Increase the hierarchy gradient by adding intermediate steps before attempting bus travel*** - A severe panic attack indicates the jump from local shops to bus travel was too large; the **anxiety hierarchy** must be adjusted to include more manageable steps to facilitate **habituation**. - Adding intermediate steps, such as sitting on a stationary bus or traveling one stop with a companion, helps rebuild **self-efficacy** and prevents the reinforcement of avoidance behavior. *Prescribe benzodiazepines to use before exposure tasks* - **Benzodiazepines** are generally contraindicated during exposure therapy as they act as a **safety behavior**, preventing the patient from experiencing the anxiety necessary for therapeutic habituation. - Using medication to suppress symptoms during exposure can lead to **state-dependent learning**, where the patient only feels capable when medicated. *Switch to medication-based treatment as psychological therapy has failed* - A single setback during **CBT** does not constitute treatment failure; setbacks are common and provide valuable clinical information about the patient's **fear hierarchy**. - First-line treatment for **panic disorder** with agoraphobia remains psychological, and adjustments to the existing protocol should be attempted before switching modalities. *Encourage immediate re-attempt of the bus journey to prevent avoidance consolidation* - Forcing an immediate re-attempt when the patient is in a state of high arousal and refusal risks **sensitization** rather than habituation, potentially traumatizing the patient further. - While preventing **avoidance consolidation** is important, it must be balanced with the patient's readiness to ensure the exposure remains **therapeutic** and not overwhelming. *Discontinue exposure therapy and focus on cognitive restructuring techniques only* - **Exposure therapy** is the most effective component for treating agoraphobic avoidance; removing it entirely would likely result in stagnant progress regarding her mobility. - **Cognitive restructuring** should complement exposure by challenging catastrophic misinterpretations of bodily sensations, but it cannot replace the behavioral experience of **extinction**.
Question 143: A 53-year-old woman with depression started on citalopram 20mg daily 10 days ago presents with confusion, agitation, tremor, hyperreflexia, and sweating. Temperature is 38.2°C. She also takes tramadol 100mg QDS for chronic back pain and St John's Wort which she didn't mention previously. What is the most likely diagnosis?
- A. Neuroleptic malignant syndrome
- B. Serotonin syndrome (Correct Answer)
- C. Anticholinergic toxicity
- D. Citalopram overdose
- E. Meningitis
Explanation: ***Serotonin syndrome***- This condition is caused by the overstimulation of central and peripheral serotonin receptors due to the combination of **citalopram**, **tramadol**, and **St John's Wort**.- Key features include the triad of **neuromuscular hyperactivity** (hyperreflexia, tremor), **autonomic instability** (tachycardia, sweating, fever), and **altered mental status** (confusion, agitation).*Neuroleptic malignant syndrome*- Typically develops over days to weeks and is associated with **dopamine antagonists** (antipsychotics) rather than SSRIs.- Characterized by **"lead-pipe" muscle rigidity** and bradyreflexia, whereas serotonin syndrome presents with **hyperreflexia** and **clonus**.*Anticholinergic toxicity*- Patients present with the classic "red as a beet, dry as a bone" signs, including **dry skin** and **decreased bowel sounds**, unlike this patient's **diaphoresis**.- It lacks the **neuromuscular irritability** like hyperreflexia and tremor seen in serotonergic excess.*Citalopram overdose*- While an overdose can cause toxicity, the patient’s symptoms are triggered by the **pharmacodynamic interaction** of multiple serotonergic agents at therapeutic doses.- Isolated SSRI overdose is less likely to produce such severe **autonomic dysfunction** and **hyperreflexia** compared to the synergistic effects of multi-drug interactions.*Meningitis*- Presents with a classic triad of **fever, headache, and nuchal rigidity**, often accompanied by photophobia.- The specific findings of **hyperreflexia** and the recent addition of **serotonergic drugs** strongly point toward a toxicological rather than infectious etiology.
Question 144: A 49-year-old man with panic disorder has been taking sertraline 100mg daily for 4 months with good control of panic attacks. He now reports experiencing 4-5 panic attacks per week again, despite medication compliance. On further questioning, he reveals he has started drinking 6-8 units of alcohol daily over the past 6 weeks to 'calm his nerves'. What is the most likely explanation for his deteriorating symptoms?
- A. Development of tolerance to sertraline requiring dose increase
- B. Alcohol-induced enhancement of GABA transmission causing rebound anxiety (Correct Answer)
- C. Hepatic enzyme induction by alcohol reducing sertraline levels
- D. Emergence of treatment-resistant panic disorder
- E. Alcohol withdrawal symptoms mimicking panic attacks
Explanation: ***Alcohol-induced enhancement of GABA transmission causing rebound anxiety*** - Alcohol acutely enhances **GABAergic** neurotransmission to provide temporary relief, but chronic use leads to **GABA receptor downregulation** and compensatory **glutamate hyperactivity**. - This neuroadaptation results in **rebound hyperexcitability** during periods of declining blood alcohol levels, which manifests as increased physiological anxiety and recurrent **panic attacks**. *Development of tolerance to sertraline requiring dose increase* - **Tolerance** to the therapeutic effects of **SSRIs** like sertraline is clinically rare once a stable and effective response has been achieved. - The sudden recurrence of symptoms specifically coincides with a significant change in lifestyle (heavy **alcohol consumption**), making pharmacological tolerance less likely. *Hepatic enzyme induction by alcohol reducing sertraline levels* - Alcohol primarily induces **CYP2E1**, whereas sertraline is metabolized mainly by **CYP2C19**, **CYP3A4**, and **CYP2B6**, minimizing the risk of a significant pharmacokinetic interaction. - Even if minor induction occurred, the profound neurochemical impact of 6-8 units of alcohol daily is a far more potent driver of **anxiety relapse** than a slight drop in serum drug levels. *Emergence of treatment-resistant panic disorder* - Treatment resistance is usually considered when there is non-response to adequate trials, not when a patient who was previously **stable** experiences a relapse due to a new **confounding factor**. - The patient’s clinical deterioration is temporally linked to the initiation of heavy drinking, suggesting a **substance-induced** exacerbation rather than a change in the primary disorder's nature. *Alcohol withdrawal symptoms mimicking panic attacks* - While **acute withdrawal** can mimic panic, the patient is drinking daily; the rebound anxiety described occurs frequently as alcohol levels fluctuate, even before formal withdrawal starts. - This option is less encompassing than the GABA/Glutamate rebound mechanism, which explains the **deteriorating baseline** of panic control specifically within the context of **co-occurring alcohol use**.
Question 145: A 41-year-old woman presents with a 2-month history of low mood, anhedonia, and significant psychomotor retardation. She has difficulty getting out of bed and has been off work for 3 weeks. PHQ-9 score is 23. She has no suicidal ideation. Her GP considers referral thresholds. Which action is most appropriate?
- A. Initiate SSRI and review in 2 weeks in primary care
- B. Refer urgently to crisis resolution home treatment team
- C. Refer routinely to community mental health team for assessment
- D. Refer to IAPT for high-intensity CBT
- E. Initiate SSRI and refer to secondary care mental health services (Correct Answer)
Explanation: ***Initiate SSRI and refer to secondary care mental health services*** - The patient exhibits **severe depression** (PHQ-9 score 23) with significant **psychomotor retardation** and severe **functional impairment** (off work for 3 weeks, difficulty getting out of bed), necessitating both immediate pharmacological intervention and specialist management. - NICE guidelines recommend that for severe depression, especially with marked functional impairment or complex features, a combination of antidepressant medication and **referral to secondary care mental health services** is the most appropriate course of action for comprehensive assessment and management. *Initiate SSRI and review in 2 weeks in primary care* - While initiating an **SSRI** is appropriate, the **severity of her symptoms** (PHQ-9 23, psychomotor retardation, off work for 3 weeks) necessitates more than just primary care follow-up. - Severe depression with such **significant functional impairment** typically requires a multidisciplinary approach and the resources of secondary care for optimal management and monitoring. *Refer urgently to crisis resolution home treatment team* - Crisis resolution teams are for patients with **immediate acute risk**, such as active suicidal ideation, severe self-harm, or rapid deterioration requiring acute intervention to prevent hospital admission. - The patient explicitly states **no suicidal ideation**, and while severely depressed, her presentation does not meet the criteria for an urgent crisis referral, which is typically for more imminent safety concerns. *Refer routinely to community mental health team for assessment* - A routine referral would mean a delay in initiating treatment, which is not appropriate for **severe depression** with significant functional impairment where prompt intervention is crucial. - While referral to a **community mental health team (CMHT)** is part of the correct management, it should be concurrent with **initiation of an SSRI**, not just a referral for assessment. *Refer to IAPT for high-intensity CBT* - **IAPT (Improving Access to Psychological Therapies)** services are generally designed for mild to moderate depression and anxiety; this patient's **severe depression** and functional impairment exceed the typical scope for primary care IAPT. - While CBT can be beneficial, for **severe depression**, it is often more effective when delivered as part of a comprehensive treatment plan within **secondary care mental health services**, alongside pharmacological treatment and specialist oversight.
Question 146: A 35-year-old teacher with generalised anxiety disorder has been receiving CBT for 10 weeks with some improvement but continues to have significant functional impairment. She is reluctant to take medication but agrees to consider pharmacotherapy. She has no other medical conditions. According to NICE guidelines, which medication should be offered first-line?
- A. Pregabalin 150mg twice daily
- B. Diazepam 5mg three times daily
- C. Sertraline 50mg daily (Correct Answer)
- D. Propranolol 40mg twice daily
- E. Buspirone 5mg three times daily
Explanation: ***Sertraline 50mg daily*** - According to **NICE guidelines (CG113)**, **Selective Serotonin Reuptake Inhibitors (SSRIs)** are the first-line pharmacological treatment for **Generalised Anxiety Disorder (GAD)** when psychological therapies are insufficient. - **Sertraline** is a recommended initial choice among SSRIs due to its effectiveness, generally favorable tolerability profile, and strong evidence base for managing GAD symptoms. *Pregabalin 150mg twice daily* - **Pregabalin** is an effective treatment for GAD but is considered a **second-line** option or an alternative if SSRIs or SNRIs are not tolerated or are ineffective. - It is not the initial pharmacotherapy recommended by NICE guidelines for a patient without contraindications to SSRIs. *Diazepam 5mg three times daily* - **Benzodiazepines** like diazepam are NOT recommended for the long-term management of GAD due to the significant risk of **dependence**, tolerance, and withdrawal symptoms. - They should only be used for **short-term crisis management** of severe anxiety, typically for no more than 2-4 weeks. *Propranolol 40mg twice daily* - **Beta-blockers** such as propranolol can help alleviate the **physical symptoms** of anxiety, such as palpitations and tremors. - However, they do not target the core psychological or cognitive symptoms of **Generalised Anxiety Disorder** and are not recommended as a first-line treatment for the disorder itself. *Buspirone 5mg three times daily* - **Buspirone** is an anxiolytic that acts on serotonin receptors but is generally less effective than SSRIs for GAD and has a slower onset of action. - It is typically considered a **third-line** or adjunctive treatment option, not a first-line agent, especially when SSRIs are appropriate.
Question 147: A 58-year-old woman with recurrent depressive disorder has been taking fluoxetine 40mg daily for 6 weeks with minimal improvement. She reports persistent low mood, poor sleep, and has lost 4kg in weight. She mentions that her mother responded well to a 'different type of antidepressant' years ago. Examination reveals a blood pressure of 168/95 mmHg. Which antidepressant change should be avoided?
- A. Switch to sertraline 100mg daily
- B. Switch to mirtazapine 30mg at night
- C. Switch to vortioxetine 10mg daily
- D. Switch to phenelzine 15mg three times daily (Correct Answer)
- E. Switch to venlafaxine 75mg twice daily
Explanation: ***Switch to phenelzine 15mg three times daily*** - **Phenelzine** is a non-selective **monoamine oxidase inhibitor (MAOI)** that carries a high risk of **hypertensive crisis** and is contraindicated in patients with uncontrolled hypertension. - Switching from **fluoxetine** to an **MAOI** is particularly dangerous and requires a **5-week washout period** due to the long half-life of fluoxetine and the risk of **Serotonin Syndrome**. *Switch to sertraline 100mg daily* - This is an **SSRI** with a different side-effect profile that generally does not cause significant **blood pressure elevation**. - While the patient failed fluoxetine, switching to another **SSRI** is a common clinical step before moving to more complex classes. *Switch to mirtazapine 30mg at night* - **Mirtazapine** is a **noradrenergic and specific serotonergic antidepressant (NaSSA)** that often causes **weight gain** and **sedation**, which may benefit this patient’s weight loss and poor sleep. - It has a low risk of increasing **blood pressure** compared to SNRIs or MAOIs, making it a safer option for this patient. *Switch to vortioxetine 10mg daily* - **Vortioxetine** is a **multimodal** antidepressant that lacks the significant stimulatory effect on blood pressure seen with other classes. - It is often considered when patients have failed standard **SSRIs** and is generally well-tolerated in patients with cardiovascular comorbidities. *Switch to venlafaxine 75mg twice daily* - **Venlafaxine**, an **SNRI**, can cause dose-dependent **hypertension**, but it is generally easier to monitor and manage than an **MAOI**. - While it requires caution in patients with high blood pressure, it is not as strictly avoided or as pharmacologically complex to initiate as **phenelzine**.
Question 148: A 27-year-old woman presents to the emergency department with her third panic attack this month. She describes sudden onset of chest pain, palpitations, sweating, and a feeling of impending doom lasting 15-20 minutes. ECG shows sinus tachycardia. Troponin is negative. She is otherwise healthy. What is the most appropriate immediate management?
- A. Admit for 24-hour cardiac monitoring
- B. Prescribe propranolol 10mg PRN for future attacks
- C. Provide reassurance, breathing techniques, and arrange GP follow-up (Correct Answer)
- D. Commence sertraline 50mg daily immediately
- E. Prescribe diazepam 5mg PRN for symptom relief
Explanation: ***Provide reassurance, breathing techniques, and arrange GP follow-up*** - After ruling out life-threatening cardiac causes with a **normal ECG** and **negative troponin**, reassurance is crucial to alleviate the patient's immediate fear of impending doom. - Teaching **breathing techniques** provides an immediate coping strategy, while arranging **GP follow-up** ensures appropriate long-term management for recurrent panic attacks. *Admit for 24-hour cardiac monitoring* - There is no clinical indication for admission as **acute cardiac pathology has been excluded** by the negative troponin and normal ECG in an otherwise healthy young woman. - Admitting the patient for further cardiac monitoring might inadvertently **reinforce her health anxiety** and validate a non-cardiac etiology. *Prescribe propranolol 10mg PRN for future attacks* - While **beta-blockers** like propranolol can help reduce some somatic symptoms such as palpitations and tremor, they do not address the underlying psychological component of panic disorder. - They are generally not considered **first-line for acute panic attack management** or long-term treatment, which focuses on psychological therapy or SSRIs. *Commence sertraline 50mg daily immediately* - **Selective Serotonin Reuptake Inhibitors (SSRIs)** are a first-line long-term treatment for panic disorder, but their initiation typically requires a full psychiatric assessment and ongoing monitoring. - Starting an antidepressant in the emergency department is not ideal, as SSRIs can cause an **initial increase in anxiety** and side effects, requiring careful titration and follow-up not feasible in an ED setting. *Prescribe diazepam 5mg PRN for symptom relief* - **Benzodiazepines** provide rapid relief for acute panic symptoms, but they carry a high risk of **dependence, tolerance, and withdrawal symptoms** with regular or frequent use. - Their use for recurrent panic attacks can prevent patients from learning **adaptive coping mechanisms** and is generally discouraged as a primary long-term management strategy due to these risks.
Question 149: A 44-year-old man with treatment-resistant depression has failed to respond to adequate trials of two different SSRIs and venlafaxine. His psychiatrist considers augmentation therapy. He has type 2 diabetes and stage 3 chronic kidney disease. Which augmentation strategy requires the most careful monitoring in this patient?
- A. Addition of mirtazapine to current antidepressant
- B. Addition of quetiapine to current antidepressant
- C. Addition of lithium to current antidepressant (Correct Answer)
- D. Addition of lamotrigine to current antidepressant
- E. Addition of buspirone to current antidepressant
Explanation: ***Addition of lithium to current antidepressant***- **Lithium** is primarily excreted by the **kidneys**, and this patient has **Stage 3 Chronic Kidney Disease (CKD)**, which significantly reduces lithium clearance and increases the risk of toxicity.- It has a **narrow therapeutic index** and requires frequent monitoring of **serum lithium levels**, **renal function**, and **thyroid function**, especially in patients with pre-existing renal impairment.*Addition of mirtazapine to current antidepressant*- **Mirtazapine** is often used for augmentation but mainly carries risks of **weight gain** and **sedation**, which could complicate his diabetes management.- While it requires some dose adjustment in renal failure, it does not require the intensive **serum-level monitoring** that lithium necessitates.*Addition of quetiapine to current antidepressant*- **Quetiapine** is an atypical antipsychotic that can cause **metabolic syndrome**, potentially worsening this patient's **type 2 diabetes** control.- Although metabolic monitoring is required, it is not primarily renally cleared and is generally considered safer than lithium in the context of **Stage 3 CKD**.*Addition of lamotrigine to current antidepressant*- **Lamotrigine** is sometimes used for treatment-resistant depression but is primarily associated with a risk of **Stevens-Johnson Syndrome** rather than renal toxicity.- It is metabolized by the **liver** (glucuronidation), making it a less hazardous choice for a patient with **chronic kidney disease** compared to lithium.*Addition of buspirone to current antidepressant*- **Buspirone** is a 5-HT1A partial agonist used for augmentation that has a relatively **low side-effect profile** and does not require therapeutic drug monitoring.- While caution is advised in severe renal impairment, it does not pose the same acute risk of **nephrotoxicity** or accumulation-driven toxicity as **lithium**.
Question 150: A 31-year-old woman with panic disorder describes feeling increasingly anxious about having panic attacks in public places. She has started avoiding supermarkets and public transport. What psychological mechanism best explains the development of her avoidance behaviour?
- A. Classical conditioning through association of neutral stimuli with panic symptoms
- B. Operant conditioning through negative reinforcement of avoidance (Correct Answer)
- C. Cognitive distortion through catastrophic misinterpretation of bodily sensations
- D. Impaired habituation to anxiety-provoking stimuli
- E. Dysfunctional schema activation in response to environmental triggers
Explanation: ***Operant conditioning through negative reinforcement of avoidance*** - This mechanism explains why avoidance behaviors are maintained. When the woman avoids public places (e.g., supermarkets), she immediately experiences a reduction in her **anxiety** about having a panic attack, which acts as a **negative reinforcer**. - The relief from anxiety strengthens the avoidance behavior, making her more likely to avoid similar situations in the future to prevent the unpleasant feeling of panic. *Classical conditioning through association of neutral stimuli with panic symptoms* - **Classical conditioning** explains how an initial fear response to a previously neutral stimulus (like a public place) is acquired, as it becomes associated with an unconditioned stimulus (panic attack). - However, it primarily describes the *acquisition* of fear to specific cues, not the **maintenance of avoidance behaviors** that *reduces* an already existing aversive state. *Cognitive distortion through catastrophic misinterpretation of bodily sensations* - This cognitive mechanism is central to the *initiation* of a panic attack, where innocuous bodily sensations (e.g., slight breathlessness) are misinterpreted as signs of imminent catastrophe. - While crucial in the **panic cycle**, it doesn't directly describe the **behavioral mechanism** that explains *why* the individual *avoids* certain situations *after* experiencing fear. *Impaired habituation to anxiety-provoking stimuli* - **Habituation** is the natural decrease in emotional or physiological response to a stimulus with repeated exposure. Impaired habituation suggests that the anxiety response doesn't diminish. - While relevant to the persistence of anxiety, it focuses on the *response itself* rather than the **behavioral strategy** (avoidance) employed to cope with or prevent that response. *Dysfunctional schema activation in response to environmental triggers* - **Dysfunctional schemas** are deep-seated, maladaptive patterns of thought and belief that influence how individuals interpret events, often seen in conditions like depression or personality disorders. - This is a broader cognitive concept that explains underlying vulnerability and processing biases, but it is less specific than **operant conditioning** in explaining the *reinforcement* of a particular behavioral pattern like avoidance in panic disorder.
Practice by Chapter
Want unlimited practice?
Get full access to all questions, explanations, and performance tracking.
Start For Free